Drugs / adelbelimumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06016413 | Sep 2023 → Dec 2024 overdue | head and neck squamous cell carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adelbelimumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06016413 ↗ |
| Known as | adelbelimab | “Among them, adelbelimab is a human monoclonal antibody against programmed death ligand 1 (PD-L1), and its safety has been verified to some extent.” NCT06016413 ↗ |
| Action | Inhibit | “This study explored the efficacy of adelbelimab (PD-L1 inhibitor) combined with chemotherapy” NCT06016413 ↗ |
| Modality | Monoclonal antibody | “adelbelimab is a human monoclonal antibody against programmed death ligand 1 (PD-L1)” NCT06016413 ↗ |
| Route | Intravenous | “adelbelimumab 1200 mg intravenously” NCT06016413 ↗ |